• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Neptune Reports Fiscal Second Quarter 2024 Financial Results

    11/14/23 5:59:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NEPT alert in real time by email

    Company to host a conference call at 10:00 a.m. (Eastern Time) Wednesday, November 15, 2023, to discuss these results

    LAVAL, QC, Nov. 14, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced its financial and operating results for the three-month period ending September 30, 2023.

    Neptune Wellness Logo (CNW Group/Neptune Wellness Solutions Inc.)

    Second Quarter 2024 Financial Highlights:

    • Consolidated net revenue of $8.7 million, down from $12.0 million for the same period last year. This is largely due to a decrease in Food & Beverage revenues compared to the same period last year.
    • Gross loss of $0.6 million compared to a gross profit of $1.1 million for the same period last year. This change is due to a decrease in revenues of $3.2 million offset by a reduction in cost of sales of $1.6 million.
    • Consolidated SG&A expenses of $3.8 million compared to $15.9 million in Q2 of fiscal 2023, a decrease of $12.1 million or 76%. This was primarily due to a decrease in payroll and payroll related expenses as well as other cost cutting measures.
    • Reported second-quarter net loss of $5.3 million compared to a reported net loss of $37.3 million in the comparable period in fiscal 2023.
    • Adjusted EBITDA (non-GAAP) loss of $3.2 million compared to an Adjusted EBITDA (non-GAAP) loss of $13.7 million same period 2023.

    Second Quarter & Subsequent Business Highlights:

    • Announced that the Board of Directors had approved a plan to proceed with a spinout to Neptune shareholders of a majority of its equity interest in Sprout, which would follow the previously completed exchange by Neptune of existing Sprout debt for Sprout equity. Pursuant to the term sheet entered into with Morgan Stanley as previously announced on August 17, 2023, it is anticipated that Neptune would spin out a majority of its equity interest in Sprout to current Neptune shareholders, and Neptune would keep a retained interest of approximately 10-15%.
    • Effectively converted a substantial portion of Neptune's Sprout debt into Sprout equity resulting in Neptune having increased its Sprout ownership from 50.1% to approximately 89.5% and being removed as guarantor for Sprout Organic's Promissory notes from Morgan Stanley.
    • Announced repayment of Senior Secured Notes in full, of approximately $2.3 million, with CCUR Holdings, Inc. and Symbolic Logic, Inc. The senior secured notes had an original principal amount of $4 million and bore a fixed interest rate of 16.5% per annum.
    • Closed a public offering of common stock and warrants resulting in gross proceeds of approximately US$4.5 million.

    Conference Call Details:

    The Company will host a conference call at 10:00 a.m. (Eastern Time) Wednesday, November 15, 2023, to discuss these results. The conference call will be webcast live and can be accessed by registering on the Events and Presentations portion of Neptune's Investor Relations website at www.investors.neptunewellness.com. The webcast will be archived for approximately 90 days.

    About Neptune Wellness Solutions Inc.

    Neptune is a consumer-packaged goods company that aims to innovate health and wellness products. Founded in 1998 and headquartered in Laval, Quebec with a United States headquarters in Jupiter, Florida, the company focuses on developing a portfolio of high-quality, affordable consumer products that align with the latest market trends for natural, sustainable, plant-based and purpose-driven lifestyle brands. The company's products are available in more than 29,000 retail locations and include well-known organic food and beverage brands such as Sprout Organics, Nosh, and Nurturme, as well as nutraceuticals brands like Biodroga and Forest Remedies. With its efficient and adaptable manufacturing and supply chain infrastructure, the company can quickly respond to consumer demand, and introduce new products through retail partners and e-commerce channels. Please visit neptunewellness.com for more details.

    Disclaimer – Safe Harbor Forward–Looking Statements

    Statements in this news release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of applicable securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes", "belief", "expects", "intends", "projects", "anticipates", "will", "should" or "plans" to be uncertain and forward-looking. Forward-looking statements relate to future events or future performance and reflect management's expectations or beliefs regarding future events including, but not limited to, statements with respect to the timing of reporting quarterly results. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking statements and information included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Neptune's latest Annual Report on Form 10-K and its subsequent filings, which are available on EDGAR at www.sec.gov/edgar.shtml. All forward-looking statements in this news release are made as of the date of this news release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

    Condensed Consolidated Interim Balance Sheets (Unaudited)

    (in U.S. dollars)



    As at





    As at





    September 30, 2023





    March 31, 2023







    (Unaudited)











    Assets































    Current assets:















    Cash and cash equivalents

    $

    4,750,564





    $

    1,993,257



    Short-term investment



    17,642







    17,540



    Trade and other receivables



    4,585,960







    7,507,333



    Prepaid expenses



    2,031,710







    1,025,969



    Inventories



    12,060,951







    13,006,074



    Total current assets



    23,446,827







    23,550,173



















    Property, plant and equipment



    1,162,767







    1,403,264



    Operating lease right-of-use assets



    1,664,398







    1,941,347



    Intangible assets



    1,389,803







    1,607,089



    Goodwill



    2,428,718







    2,426,385



    Total assets

    $

    30,092,513





    $

    30,928,258



















    Liabilities and Equity (Deficiency)































    Current liabilities:















    Trade and other payables

    $

    29,832,755





    $

    27,051,561



    Current portion of operating lease liabilities



    339,620







    339,620



    Loans and borrowings



    10,208,916







    7,538,369



    Provisions



    6,870,815







    2,948,340



    Liability related to warrants



    2,508,691







    3,156,254



    Total current liabilities



    49,760,797







    41,034,144



















    Operating lease liabilities



    1,887,727







    2,017,888



    Loans and borrowings, net of current portion



    16,684,521







    15,412,895



    Other liability



    19,000







    24,000



    Total liabilities



    68,352,045







    58,488,927



















    Shareholders' Equity (Deficiency):















    Share capital - without par value (2,009,102 shares issued and outstanding as of

    September 30, 2023; 300,070 shares issued and outstanding as of March 31, 2023)



    325,219,444







    321,946,102



    Warrants



    6,582,033







    6,155,323



    Additional paid-in capital



    59,222,340







    58,138,914



    Accumulated other comprehensive loss



    (14,884,171)







    (14,538,830)



    Deficit



    (392,845,921)







    (383,641,363)



    Total deficiency attributable to equity holders of the Company



    (16,706,275)







    (11,939,854)



















    Non-controlling interest



    (21,553,257)







    (15,620,815)



    Total shareholders' deficiency



    (38,259,532)







    (27,560,669)



















    Commitments and contingencies















    Subsequent events















    Total liabilities and shareholders' deficiency

    $

    30,092,513





    $

    30,928,258



    Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

    (Unaudited) (in U.S. dollars)

    For the three period ended September 30, 2023 and 2022



    Three-month periods ended





    September 30,

    2023





    September 30,

    2022



















    Revenue from sales net of excise taxes of nil and nil (2022 - $1,600 and $643,476 )

    $

    8,714,577





    $

    11,755,056



    Royalty revenues



    25,311







    218,731



    Other revenues



    —







    13,055



    Total revenues



    8,739,888







    11,986,842



















    Cost of sales other than impairment loss on inventories



    (9,091,439)







    (10,878,974)



    Impairment loss on inventories



    (216,184)







    —



    Total cost of sales



    (9,307,623)







    (10,878,974)



    Gross profit (loss)



    (567,735)







    1,107,868



















    Research and development expenses



    (24,675)







    (207,598)



    Selling, general and administrative expenses



    (3,836,411)







    (15,907,638)



    Impairment loss related to intangible assets



    —







    (2,593,529)



    Impairment loss on assets held for sale



    —







    (14,530,458)



    Impairment loss related to goodwill



    —







    (7,570,471)



    Net gain on sale of property, plant and equipment



    —







    —



    Loss from operating activities



    (4,504,230)







    (39,701,826)



















    Finance income



    —







    16



    Finance costs



    (3,174,627)







    (379,007)



    Foreign exchange gain



    526,436







    4,613,545



    Loss on issuance of derivatives



    (157,049)







    —



    Gain (loss) on revaluation of derivatives



    1,972,952







    (1,807,890)



    Total other income (expense)



    (832,288)







    2,426,664



    Loss before income taxes



    (5,336,518)







    (37,275,162)



















    Income tax expense



    —







    (12,530)



    Net loss



    (5,336,518)







    (37,287,692)



















    Other comprehensive income (loss)















    Net change in unrealized foreign currency gains (losses) on translation of

        net investments in foreign operations (tax effect of nil for all periods)



    15,004







    (3,702,162)



    Total other comprehensive income (loss)



    15,004







    (3,702,162)



















    Total comprehensive loss

    $

    (5,321,514)





    $

    (40,989,854)



















    Net loss attributable to:















    Equity holders of the Company

    $

    (890,190)





    $

    (30,897,458)



    Non-controlling interest



    (4,446,328)







    (6,390,234)



    Net loss

    $

    (5,336,518)





    $

    (37,287,692)



















    Total comprehensive loss attributable to:















    Equity holders of the Company

    $

    (875,186)





    $

    (34,599,620)



    Non-controlling interest



    (4,446,328)







    (6,390,234)



    Total comprehensive loss

    $

    (5,321,514)





    $

    (40,989,854)



















    Basic loss per share attributable to:















    Common Shareholders of the Company

    $

    (1.38)





    $

    (151.17)



















    Diluted loss per share attributable to:















    Common Shareholders of the Company

    $

    (1.38)





    $

    (151.17)



















    Basic and diluted weighted average number of common shares



    646,813







    204,388



    SELECTED CONSOLIDATED FINANCIAL INFORMATION (in millions, except per share data)

    The following table sets out selected consolidated financial information.





    Three-month periods ended









    September 30,

    2023





    September 30,

    2022





    Total revenues



    $

    8.740





    $

    11.987





    Adjusted EBITDA1





    (3.220)







    (13.677)





    Net loss





    (5.337)







    (37.288)





    Net loss attributable to equity holders of the Company





    (0.890)







    (30.897)





    Net loss attributable to non-controlling interest





    (4.446)







    (6.390)





    Basic and diluted loss attributable to common shareholders of the Company





    (20.52)







    (29.46)





     





    As at

    September 30,

    2023





    As at

    March 31,

    2023





    As at

    March 31,

    2022



    Total assets



    $

    30.093





    $

    30.928





    $

    104.955



    Working capital2





    (26.314)







    (17.484)







    7.071



    Non-current financial liabilities





    18.591







    17.455







    13.800



    (Deficiency) equity attributable to equity holders of the Company





    (16.706)







    (11.940)







    48.116



    (Deficiency) equity attributable to non-controlling interest





    (21.553)







    (15.621)







    12.722



    1 

    The Adjusted EBITDA is a non-GAAP measure. It is not a standard measure endorsed by US GAAP requirements. A reconciliation to the Company's net loss is presented below. In the three-month period ended September 30, 2022, the Company re-casted comparative Adjusted EBITDA to conform to its current definition. As a result, the following adjustments were removed in the current and comparative quarters: litigation provisions, business acquisition and integration costs, signing bonus, severance and related costs, and write-down of inventories and deposits.

    2   

    Working capital is calculated by subtracting current liabilities from current assets. Because there is no standard method endorsed by US GAAP, the results may not be comparable to similar measurements presented by other public companies. Current assets as at September 30, 2023, March 31, 2023 and March 31, 2022 were $23.447, $23.550 and $337.388 respectively, and current liabilities as at September 30, 2023, March 31, 2023 and March 31, 2022 were $49.761, $41.034 and $30.317 respectively.

    NON-GAAP FINANCIAL PERFORMANCE MEASURES

    The Company uses one adjusted financial measure, Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") to assess its operating performance. This non-GAAP financial measure is presented in a consistent manner, unless otherwise disclosed. The Company uses this measure for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. The measure also helps the Company to plan and forecast for future periods as well as to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to its GAAP financial statements, allows them to see the Company's results through the eyes of Management, and to better understand its historical and future financial performance. Neptune's method for calculating Adjusted EBITDA may differ from that used by other corporations.

    A reconciliation of net loss to Adjusted EBITDA is presented below.

    ADJUSTED EBITDA

    Although the concept of Adjusted EBITDA is not a financial or accounting measure defined under US GAAP and it may not be comparable to other issuers, it is widely used by companies. Neptune obtains its Adjusted EBITDA measurement by excluding from its net loss the following items: net finance costs (income), depreciation and amortization, and income tax expense (recovery). Other items such as equity classified stock-based compensation, non-employee compensation related to warrants, impairment losses on non-financial assets, revaluations of derivatives, costs related to conversion from IFRS to US GAAP and other changes in fair values are also added back to Neptune's net loss. The exclusion of net finance costs (income) eliminates the impact on earnings derived from non-operational activities. The exclusion of depreciation and amortization, stock-based compensation, non-employee compensation related to warrants, impairment losses, revaluations of derivatives and other changes in fair values eliminates the non-cash impact of such items, and the exclusion of costs related to conversion from IFRS to US GAAP, together with the other exclusions discussed above, present the results of the on-going business. From time to time, the Company may exclude additional items if it believes doing so would result in a more effective analysis of underlying operating performance. Adjusting for these items does not imply they are non-recurring. For purposes of this analysis, the Net finance costs (income) caption in the reconciliation below includes the impact of the revaluation of foreign exchange rates.

    In the three-month period ended September 30, 2022, the Company recast comparative Adjusted EBITDA to conform to the current definition. As a result, the following adjustments were removed in the current and comparative quarters: litigation provisions, business acquisition and integration costs, signing bonus, severance and related costs, and write-down of inventories and deposits.

    Adjusted EBITDA1 reconciliation, in millions of dollars





    Three-month periods ended









    September 30,

    2023





    September 30,

    2022

























    Net loss for the period



    $

    (5.337)





    $

    (37.288)





    Add (deduct):



















    Depreciation and amortization





    0.373







    0.691





    Revaluation of derivatives





    (1.973)







    1.808





    Net finance costs (income)





    3.175







    (4.235)





    Equity classified stock-based compensation





    0.467







    0.640





    Impairment loss on long-lived assets





    0.075







    24.694





    Income tax expense





    —







    0.013





    Adjusted EBITDA1



    $

    (3.220)





    $

    (13.677)





    1

    The Adjusted EBITDA is not a standard measure endorsed by US GAAP requirements. In the three-month period ended September 30, 2022, the Company re-casted comparative Adjusted EBITDA to conform to its current definition. As a result, the following adjustments were removed in the current and comparative quarters: litigation provisions, business acquisition and integration costs, signing bonus, severance and related costs, and write-down of inventories and deposits.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neptune-reports-fiscal-second-quarter-2024-financial-results-301988275.html

    SOURCE Neptune Wellness Solutions Inc.

    Get the next $NEPT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEPT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neptune Appoints Interim President and CEO and Interim COO

    LAVAL, QC / ACCESSWIRE / March 8, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced the Company's Board of Directors has named Board member Michael De Geus Interim President and Chief Executive Officer, effective immediately. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals, Inc. ("Biodroga"), Interim C

    3/8/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Decision of Nasdaq Hearings Panel To Delist Common Shares

    LAVAL, QC / ACCESSWIRE / March 6, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced an update on the status of its appeal against the determination of the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") to delist the Company's common shares ("Common Shares").As previously disclosed, the Company had been notified by Nasdaq on November 30, 2023 that it was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below US$1.00 for 30 consecutive trading days and that it was not in comp

    3/6/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Michael Cammarata's Resignation Effective February 23, 2024

    LAVAL, QC / ACCESSWIRE / March 4, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced that Michael Cammarata has resigned from his role as President and Chief Executive Officer effective February 23, 2024. We thank Michael for his service and wish him best of luck in his future endeavors.About Neptune Wellness Solutions Inc.Neptune is a consumer-packaged goods company that aims to innovate health and wellness products. Founded in 1998 and headquartered in Laval, Quebec with a United States headquarters in Jupiter, Florida, the company focuses on developing a portfolio of high-quality, affordable consumer products that align with the latest marke

    3/4/24 8:31:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    SEC Filings

    View All

    Neptune Wellness Solutions Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Neptune Wellness Solutions Inc. (0001401395) (Filer)

    5/6/24 2:26:26 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Neptune Wellness Solutions Inc.

    25-NSE - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    4/25/24 9:09:07 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Wellness Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K - Neptune Wellness Solutions Inc. (0001401395) (Filer)

    4/12/24 5:02:21 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Neptune Securities Settlement Fund sold $13,601 worth of shares (200,300 units at $0.07), decreasing direct ownership by 25% to 1,048,334 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    4/30/24 12:01:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Securities Settlement Fund sold $35,224 worth of shares (81,814 units at $0.43), decreasing direct ownership by 7% to 1,671,302 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    3/6/24 11:04:07 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Securities Settlement Fund sold $187,949 worth of shares (247,604 units at $0.76), decreasing direct ownership by 12% to 1,778,380 units (SEC Form 4)

    4 - Neptune Wellness Solutions Inc. (0001401395) (Issuer)

    11/30/23 5:26:53 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Leadership Updates

    Live Leadership Updates

    View All

    Neptune Appoints Interim President and CEO and Interim COO

    LAVAL, QC / ACCESSWIRE / March 8, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced the Company's Board of Directors has named Board member Michael De Geus Interim President and Chief Executive Officer, effective immediately. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals, Inc. ("Biodroga"), Interim C

    3/8/24 8:30:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Reports Fiscal Third Quarter 2024 Financial Results

    LAVAL, QC / ACCESSWIRE / February 16, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced its financial and operating results for its fiscal third quarter 2024 ending December 31, 2023.Recent Business HighlightsAnnounced the appointment of Stifel Nicolaus Canada Inc. ("Stifel") to act as exclusive financial advisor to the Company's organic baby food and toddler brand, Sprout Foods Inc. ("Sprout Organics"), providing financial advisory, investment banking services, and strategic advice regarding the review of divestiture alternatives related

    2/16/24 5:35:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Retains Stifel to Explore Strategic Alternatives for Sprout Organics

    LAVAL, QC / ACCESSWIRE / January 24, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced the appointment of Stifel Nicolaus Canada Inc. ("Stifel") to act as exclusive financial advisor to the Company's organic baby food and toddler brand, Sprout Foods Inc. ("Sprout Organics"), providing financial advisory, investment banking services, and strategic advice regarding the review of divestiture alternatives related to Sprout Organics.Stifel brings a wealth of experience and expertise in the financial sector, having successfully facilitated nume

    1/24/24 9:00:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Financials

    Live finance-specific insights

    View All

    Neptune Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results

    Consolidated revenues for fiscal 2023 totaled $52.6 million, an increase of $3.8 million or 7.8% as compared to $48.8 million for fiscal 2022 Q4 net sales $12.1 million, up 5% from last year's $11.5 million Sprout maintained a top 3 brand position on Amazon in fiscal 2023 and strong sales levels in all periods nationally1 Sprout was available in 90% of footprint the Organic Baby Food market across all 50 U.S. states and Canada Company to host a conference call at 5:00 p.m. (Eastern Time) on Tuesday, July 18, 2023 LAVAL, QC, July 17, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustai

    7/17/23 5:38:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune to Report Fiscal Third Quarter 2023 Financial Results on March 30, 2023

    Company to host a conference call at 5:00 p.m. (Eastern Time) LAVAL, QC, March 30, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, announced today that it will report its financial results for the third quarter of fiscal 2023 after the market close on Thursday, March 30, 2023. The Company will host a conference call at 5:00 p.m. (Eastern Time) today, Thursday, March 30, 2023, to discuss these results. The conference call wil

    3/30/23 11:28:00 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neptune Announces Receipt of NASDAQ Notification

    LAVAL, QC, Feb. 24, 2023 /PRNewswire/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT) ), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, today announced that the Company has received written notification from the Listing Qualification Department of the Nasdaq Stock Market LLC on February 23, 2023, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), as a result of Neptune not having timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2022 with the U.S. Securities and Exchange Commission.  

    2/24/23 4:05:00 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NEPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Neptune Wellness Solutions Inc. (Amendment)

    SC 13G/A - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    2/12/24 6:48:47 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Neptune Wellness Solutions Inc. (Amendment)

    SC 13G/A - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    1/2/24 2:02:04 PM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Neptune Wellness Solutions Inc.

    SC 13D - Neptune Wellness Solutions Inc. (0001401395) (Subject)

    10/17/23 11:57:17 AM ET
    $NEPT
    Biotechnology: Pharmaceutical Preparations
    Health Care